Diabetes, one of the most common chronic health conditions, impacts multiple body parts over the time. Very few know that one of the important parts of the body that is often affected by diabetes, is the vagus nerve. This nerve normally regulates the activity of the emptying of stomach but diabetes damages the nerve, making it difficult to function normally. This ultimately results in decelerated digestion process and thus delayed emptying. The global diabetic gastroparesis treatment market is expected to register a CAGR of 4.1% over the forecast period (2016–2024) and reach a market valuation of US$ 3,769.3 Mn by 2024.
In a nutshell, diabetes can damage the vagus nerve due to which, food stays in a patient’s body for much longer that it should normally. This condition associated with diabetes is termed as diabetic gastroparesis (DGP), which is one of the major causes of blood sugar level hindrance.
Normally, the level of blood glucose plays a key role in the process of stomach emptying, which makes it necessary to have a maintained level of blood glucose. However, when the blood glucose levels are elevated in a diabetic patient, they directly hamper stomach emptying and complicate blood glucose control. This is diabetic gastroparesis that can be addressed with a primary aim of facilitating gastric emptying, gaining better control of blood sugar levels thereby.
Request For Report Sample: https://www.researchreportinsights.com/report/sample/110114745/Diabetic-Gastroparesis-Treatment-Market
DGP May Affect Diabetes Type 1 and Type 2 Patients
Although there may be various causes of gastroparesis, diabetes is the most common among them. Patients suffering from diabetes from more than 10 years usually develop gatsroparesis along with other diabetes-relates complications. DGP is more common in patients with diabetes type 1; however, those with diabetes type 2 may also suffer from it.
While DGP may affect around 25-65% of diabetes mellitus type 1 population, it may inflict nearly 30% of the diabetes mellitus type 2 patients. Moreover, research indicates that this condition is more pronounced among women than in male patients.
Key Symptoms of DGP
Typically characterized nausea, vomiting, post-prandial fullness, stomach bloating, early satiety, loss of appetite, heartburn, and acid reflux without vomiting or nausea, diabetic gastroparesis primarily involves delayed emptying of stomach without any mechanical obstruction. The aforementioned symptoms of DGP can be within mild to extremely troubling, and are usually manageable. However, a severe stage of DGP involves substantial weight loss, malnutrition, and insufficient oral intake, which can be difficult to manage. A patient with severe diabetic gastroparesis may need hospitalization more frequently, compared to other diabetes patients.
Request For Report TOC: https://www.researchreportinsights.com/report/rd/110114745/Diabetic-Gastroparesis-Treatment-Market#menu1
DGP Treatment
When it comes to DGP treatment, the process predominantly includes symptom management, followed by medication and appropriate diet regimen. For improving symptoms and stabilizing blood glucose levels, gastroparesis patients are often recommended liquid diet and multiple pureed meals a day.
One of the treatment options often considered by physicians in case of strong nausea and vomiting symptoms, is gastric electrical stimulation. It involves surgical implantation of a device in a patient’s abdomen and primarily aims to reduce vomiting and nausea. The device functions to send electrical pulses to the lower abdomen, especially the nerves and smooth muscles, which ultimately improves vomiting and nausea.
Global Market Dynamics
The global market for diabetic gastroparesis treatment is a multibillion dollar industry, growing impressively since the recent past. With increasing incidences of diabetes type 1 and type 2, the market is expected to gain immense traction in the long run. The overall market growth will remain steady over the forecast period 2016-2024.
Projected to exceed US$ 3.5 Bn revenues by the end of 2024, the market will witness a CAGR of 4.1%. Along with popularly used drugs for DGP symptom management, a few surgical intervention options are also gaining popularity owing to their ability to provide long term relief. Regional analysis suggests that North America and Asia Pacific will remain the key markets for diabetic gastroparesis treatment in the near future.
Janssen Global Services, LLC, Salix Pharmaceuticals, Inc., Abbott Laboratories, Medtronic, C. R. Bard, Inc., Kimberly-Clark Corporation, Boston Scientific Corporation, Cardinal Health, Inc., Rhythm Pharmaceuticals, Inc., Evoke Pharma, and Alfa Wassermann SPA are some of the leading players operating in the global diabetic gastroparesis treatment market.
Report Analysis: https://www.researchreportinsights.com/report/rd/110114745/Diabetic-Gastroparesis-Treatment-Market
The Global Diabetic Gastroparesis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026 gives an evaluation of the market developments based on historical studies and comprehensive research respectively.
The market segments are also provided with an in-depth outlook of the competitive landscape and a listing of the profiled key players.The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved.
The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.The report classifies the market into different segments based on product type, disease indication and distribution channel.
These segments are studied in detail incorporating the market estimates and forecasts at regional and country level.
The segment analysis is useful in understanding the growth areas and probable opportunities of the market.Leading Segment in this market:By Product Type – DrugsBy Disease Indication – Compensated GastroparesisBy Geography – North AmericaFinal Report will cover the impact of COVID-19 on this industry.Browse the complete Global Diabetic Gastroparesis Treatment Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026 @ https://www.decisiondatabases.com/ip/10956-diabetic-gastroparesis-treatment-market-reportThe report also covers the complete competitive landscape of the global Diabetic Gastroparesis Treatment market with company profiles of key players such as:Salix Pharmaceuticals, Inc.Abbott LaboratoriesMedtronicC.
R. Bard, Inc.Halyard Health Inc.Boston Scientific CorporationCardinal Health, Inc.A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.SEGMENTATIONS IN THE REPORT:By Product Type:DrugsGastroprokinetic AgentsAntiemetic AgentsBotulinum ToxinSurgical Treatment ProductsGastric Electrical Stimulation DevicesPercutaneous Endoscopic Gastroscopic KitParenteral NutritionBy Disease Indication:Compensated GastroparesisGastric FailureBy Distribution Channel:Hospital PharmaciesPrivate ClinicsDrug StoresRetail PharmaciesE-CommerceBy Geography:North America (NA)Europe (EU)Asia Pacific (APAC)Latin America (LA)Middle East & Africa (MEA)Download Free Sample Report of Global Diabetic Gastroparesis Treatment Market @ https://www.decisiondatabases.com/contact/download-sample-10956The Global Diabetic Gastroparesis Treatment Market has been exhibited in detail in the following chapters –Chapter 1 Diabetic Gastroparesis Treatment Market PrefaceChapter 2 Executive SummaryChapter 3 Diabetic Gastroparesis Treatment Industry AnalysisChapter 4 Diabetic Gastroparesis Treatment Market Value Chain AnalysisChapter 5 Diabetic Gastroparesis Treatment Market Analysis By Product TypeChapter 6 Diabetic Gastroparesis Treatment Market Analysis By Disease IndicationChapter 7 Diabetic Gastroparesis Treatment Market Analysis By Distribution ChannelChapter 8 Diabetic Gastroparesis Treatment Market Analysis By GeographyChapter 9 Competitive Landscape Of Diabetic Gastroparesis Treatment CompaniesChapter 10 Company Profiles Of Diabetic Gastroparesis Treatment IndustryPurchase the complete Global Diabetic Gastroparesis Treatment Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-10956Other Reports by DecisionDatabases.com:Global LASIK Treatment Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026Global Aspergillosis Treatment Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026Global Bovine Respiratory Disease Treatment Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
The Global Diabetic Gastroparesis Treatment Market over USD 4 billion in 2030 and is to grow with a CAGR over 3.8% from 2020-2030.
The condition happens in patients experiencing both Type 1& 2 diabetes and is increasingly normal in female patients experiencing type-2 diabetes.
The condition includes postponed purging of the stomach prompting a progression of side effects, for example, vomiting, nausea, abdominal bloating, weight loss, abdominal pain, spasms of the stomach wall, heartburn and gastroesophageal reflux.Market Dynamics and Factors:Major growth factors, for instance rising commonness of diabetic gastroparesis with high neglected clinical needs and accessibility of in-patient hospital stays reimbursements in developing nations should accelerate global diabetic gastroparesis treatment market over the forecasted time period.
Likewise, expanding affrodability among individuals and ease of medicines accessibitlty are additionally expected to help diabetic gastroparesis treatment demand growth.
However, utilization of non-doctor prescribed medications to control symptoms leads to restricting diagnosis of stage 1 & 2 gastroparesis.
Absence of clinical proof on progress offered by physician endorsed medications and end of clinical preliminaries are factors expected to hamper global diabetic gastroparesis treatment market growth.Download Research Sample with Industry Insights @ https://www.trendsmarketresearch.com/report/sample/13671Market Segmentation:Based on the type of disease, the diabetic gastroparesis treatment industry is segmented into Drugs (Antiemetic Agents, Gastroprokinetic Agents & Botulinum Toxin) and Surgical Treatment Products (Percutaneous Endoscopic Gastrostomy (PEG) Kit, Gastric Electrical Stimulation (GES) Device & Parenteral Nutrition).
Market Analysis and Insights:- Global Diabetic Gastroparesis Treatment MarketGlobal Diabetic Gastroparesis Treatment Market By Indication Type (Compensated Gastroparesis, Gastric Failure), Treatment (Medication, Surgery), Drugs (Gastroprokinetic Agents, Antiemetic Agents, Botulinum Toxin and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026Market Analysis: Global Diabetic Gastroparesis Treatment MarketGlobal diabetic gastroparesis treatment market is expected to grow at a healthy CAGR in the forecast period of 2019-2026.
Emergence of drugs used to treat diabetic gastroparesis and high demand of disease specific novel therapies are the key factors that fueling the market growthMarket Definition: Global Diabetic Gastroparesis Treatment MarketGastroparesis is also called as delayed gastric emptying is condition of abnormal gastric motility which results in slow gastric emptying.
People with diabetic gastropareses often experience heartburn, nausea, vomiting of undigested food, loss of appetite etc.Get More Insight About the Global Diabetic Gastroparesis Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-diabetic-gastroparesis-treatment-marketMarket DriversVulnerable diabetic population worldwide is fueling the growth of this marketIncrease in special designation from the regulatory authorities is drive the marketHuge financial support to the researchers for developing novel intervention is boosting the market growthHigh demand of disease specific novel treatment can also act as a market driverMarket RestraintsLimited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this marketLow healthcare budget in some developing countries is hamper the market growthKnow More this Report @ https://www.databridgemarketresearch.com/reports/global-diabetic-gastroparesis-treatment-marketSegmentation: Global Diabetic Gastroparesis Treatment MarketBy Indication TypeCompensated GastroparesisGastric FailureBy TreatmentMedicationSurgeryBy DrugsGastroprokinetic AgentsMetoclopramidePrucloprideAntiemetic AgentsProchlorperazineOndansetronBotulinum ToxinOthersBy Route of AdministrationOralInjectableBy End UsersHospitalsHomecareSpecialty ClinicsOthersBy Distribution ChannelHospital PharmaciesRetail PharmaciesOthersBy GeographyNorth AmericaU.S.CanadaMexicoSouth AmericaBrazilRest of South AmericaEuropeGermanyFranceUnited KingdomItalySpainRussiaTurkeyBelgiumNetherlandsSwitzerlandRest of EuropeAsia-PacificJapanChinaSouth KoreaIndiaAustraliaSingaporeThailandMalaysiaIndonesiaPhilippinesRest of Asia PacificMiddle East & AfricaSouth AfricaRest of Middle East & AfricaKey Developments in the Market:In May 2019, Allergan expanded PLEDGE program with a fifth study with relamorelin, a ghrelin agonist being studied for the treatment of diabetic gastroparesis (DG).
If trial successful it will change treatment paradigms across gastroenterology and improve the millions of people suffering from the debilitating effects of diabetic gastroparesis.In December 2016, Theravance Biopharma received Fast Track designation from the FDA for velusetrag (TD-5108), an oral once-daily selective 5-hydroxtryptamine 4 (5-HT4) receptor agonist for the treatment of symptoms associated with idiopathic and diabetic gastroparesis.
With this designation enables the company to accelerate the development process which helps patients to have access on the treatment as quickly as possible.Competitive Analysis:Global Diabetic Gastroparesis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
The report includes market shares of Global Diabetic Gastroparesis treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.Key Market Players:Few of the major competitors currently working in the global diabetic gastroparesis treatment market are Theravance Biopharma, Allergan, GlaxoSmithKline plc, Endologic, Evoke Pharma, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Vanda Pharmaceuticals, F. Hoffmann-La Roche Ltd, CINRX, Ironwood Pharmaceuticals, Inc, ANI Pharmaceuticals, Inc, Bausch Health, RHYTHM PHARMACEUTICALS, INC, Teva Pharmaceutical Industries Ltd, WOCKHARDT, Fresenius Kabi AG, Pfizer Inc, Ipca Laboratories Ltd, Vintage Labs and othersResearch Methodology: Global Diabetic Gastroparesis Treatment MarketData collection and base year analysis is done using data collection modules with large sample sizes.
Market Overview:The Global Diabetic Gastroparesis Treatment Market over USD 4 billion in 2030 and is to grow with a CAGR over 3.8% from 2020-2030.
The condition happens in patients experiencing both Type 1& 2 diabetes and is increasingly normal in female patients experiencing type-2 diabetes.
The condition includes postponed purging of the stomach prompting a progression of side effects, for example, vomiting, nausea, abdominal bloating, weight loss, abdominal pain, spasms of the stomach wall, heartburn and gastroesophageal reflux.Market Dynamics and Factors:Major growth factors, for instance rising commonness of diabetic gastroparesis with high neglected clinical needs and accessibility of in-patient hospital stays reimbursements in developing nations should accelerate global diabetic gastroparesis treatment market over the forecasted time period.
Likewise, expanding affrodability among individuals and ease of medicines accessibitlty are additionally expected to help diabetic gastroparesis treatment demand growth.
However, utilization of non-doctor prescribed medications to control symptoms leads to restricting diagnosis of stage 1 & 2 gastroparesis.
Absence of clinical proof on progress offered by physician endorsed medications and end of clinical preliminaries are factors expected to hamper global diabetic gastroparesis treatment market growth.Request for Sample with Complete TOC and Figures & Graphs @ https://www.trendsmarketresearch.com/report/sample/13671 Market Segmentation:Based on the type of disease, the diabetic gastroparesis treatment industry is segmented into Drugs (Antiemetic Agents, Gastroprokinetic Agents & Botulinum Toxin) and Surgical Treatment Products (Percutaneous Endoscopic Gastrostomy (PEG) Kit, Gastric Electrical Stimulation (GES) Device & Parenteral Nutrition).
